Phase II, randomized, open-label and multicenter study to evaluate the effect of oral metronomic vinorelbine versus best supportive treatment as maintenance therapy after taxane-based first-line chemotherapy in patients with treatment-resistant HER-2 negative breast cancer. endocrine
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: FISABIO
- Phase: II
- Execution start: 17/01/2017
- End of execution: 30/08/2020
- IP: ENCARNA GONZALEZ FLORES